William Fumey

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

G. Adam, F. Koch-Nolte, P. Bannas, 2015, Journal of visualized experiments : JoVE.

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

F. Koch-Nolte, P. Bannas, K. Weisel, 2022, Frontiers in Immunology.

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

G. Adam, N. Kröger, G. Schuch, 2020, Theranostics.

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells

S. Menzel, F. Koch-Nolte, P. Bannas, 2018, Front. Immunol..

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo

G. Adam, F. Malavasi, S. Menzel, 2017, Scientific Reports.

Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection.

G. Adam, F. Koch-Nolte, H. Ittrich, 2015, Contrast media & molecular imaging.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies

C. Bokemeyer, B. Fehse, K. Riecken, 2019, Molecular Cancer Therapeutics.